AI Article Synopsis
- - The study focuses on addressing the challenges of selecting and delivering siRNA for treating hepatitis B virus (HBV) by targeting the HBx gene.
- - Researchers developed a specific siRNA expression plasmid that inhibits HBx using a dual-luciferase system for selection.
- - The effective delivery of this siRNA plasmid was achieved using PEG-modified cationic liposomes, demonstrating significant inhibition of HBx expression in both cell cultures and animal models.
Article Abstract
In order to solve the problem of selection and in vivo delivery problem in siRNA treatment, hepatitis B virus (HBV) HBx gene which could be targeted by siRNA was studied. The siRNA expression plasmid which specific inhibits HBx expression was obtained by in vitro selection via a dual-luciferase plasmid including HBx-Fluc fusion protein expression domain. The selected siRNA expression plasmid was then encapsulated in PEG-modified cationic liposome, which was devoted into pharmacodynamic studies at both cellular and animal level. The results illustrated that the cationic liposome which encapsulated siRNA expression plasmid could effectively inhibit HBx gene expression both in vitro and in vivo.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!